Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | CYC140 |
Synonyms | |
Therapy Description |
CYC140 is an ATP-competitive inhibitor of Plk1, which may lead to cell cycle arrest and inhibition of tumor cell growth (Cancer Res 2017;77(13 Suppl):Abstract nr 4178). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
CYC140 | CYC 140|CYC-140 | PLK1 Inhibitor 18 | CYC140 is an ATP-competitive inhibitor of Plk1, which may lead to cell cycle arrest and inhibition of tumor cell growth (Cancer Res 2017;77(13 Suppl):Abstract nr 4178). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03884829 | Phase I | CYC140 | A Phase I Study of CYC140, a PLK-1 Inhibitor, in Advanced Leukemias or MDS | Terminated | USA | 0 |
NCT05358379 | Phase Ib/II | CYC140 | A Study to Investigate CYC140, in Subjects With Advanced Solid Tumors and Lymphoma | Recruiting | USA | ESP | 1 |